Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz‐Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon Martínez‐Arranz, Ainhoa Lapitz, Alvaro Santos‐Laso, Matias A. Avila, Maria L. Martínez‐Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias – 16 October 2018 – Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge.

Fien A. von Meijenfeldt, Ton Lisman – 16 October 2018

Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz‐Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon Martínez‐Arranz, Ainhoa Lapitz, Alvaro Santos‐Laso, Matias A. Avila, Maria L. Martínez‐Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias – 16 October 2018 – Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge.

Nicholas O. Davidson – 16 October 2018

Helene Gellert‐Kristensen, Nawar Dalila, Sune Fallgaard Nielsen, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Stefan Stender – 16 October 2018 – Gallstone disease is a common complex disease that confers a substantial economic burden on society. The genetic underpinnings of gallstone disease remain incompletely understood. We aimed to identify genetic associations with gallstone disease using publicly available data from the UK Biobank and two large Danish cohorts.

Helene Gellert‐Kristensen, Nawar Dalila, Sune Fallgaard Nielsen, Børge Grønne Nordestgaard, Anne Tybjærg‐Hansen, Stefan Stender – 16 October 2018 – Gallstone disease is a common complex disease that confers a substantial economic burden on society. The genetic underpinnings of gallstone disease remain incompletely understood. We aimed to identify genetic associations with gallstone disease using publicly available data from the UK Biobank and two large Danish cohorts.

Arvin Iracheta‐Vellve, Charles D. Calenda, Jan Petrasek, Aditya Ambade, Karen Kodys, Luciano Adorini, Gyongyi Szabo – 15 October 2018 – Bile acids (BAs) activate various dedicated receptors, including the farnesoid X receptor (FXR) and the Takeda G protein‐coupled receptor 5 (TGR5). The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising results in NASH patients, whereas TGR5 agonists target inflammation and metabolism.

Philip Rosenthal, Simon C. Ling, Steven H. Belle, Karen F. Murray, Norberto Rodriguez‐Baez, Sarah J. Schwarzenberg, Jeffrey Teckman, Hsing‐Hua S. Lin, Kathleen B. Schwarz, for the Hepatitis B Research Network (HBRN) – 15 October 2018 – The optimal management strategy for children with immune‐tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune‐tolerant phase of HBV infection.

Philip Rosenthal, Simon C. Ling, Steven H. Belle, Karen F. Murray, Norberto Rodriguez‐Baez, Sarah J. Schwarzenberg, Jeffrey Teckman, Hsing‐Hua S. Lin, Kathleen B. Schwarz, for the Hepatitis B Research Network (HBRN) – 15 October 2018 – The optimal management strategy for children with immune‐tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune‐tolerant phase of HBV infection.

Juan G. Abraldes, Jonel Trebicka, Naga Chalasani, Gennaro D’Amico, Don C. Rockey, Vijay H. Shah, Jaime Bosch, Guadalupe Garcia‐Tsao – 15 October 2018 – Portal hypertension (PH) is the main driver of cirrhosis decompensation, the main determinant of death in patients with cirrhosis. PH results initially from increased intrahepatic vascular resistance. Subsequently, increased inflow from splanchnic vasodilation and increased cardiac output lead to a further increase in portal pressure (PP). Reducing PP in cirrhosis results in better outcomes. Removing the cause of cirrhosis might improve PP.